Takeda Updates FY2025 Guidance with Slight Revenue Increase, Non-GAAP EPS at ¥428.00

Takeda Pharmaceutical has revised its FY2025 guidance with a slight revenue increase to ¥4,530.0 billion, up from the previous projection of ¥4,500.0 billion. The company's non-GAAP EPS for the nine-month period is ¥428.00, with a 3.3% year-over-year revenue decline. Takeda's focus on VYVANSE contributions, cost management, and favorable foreign exchange impacts has contributed to the revised guidance.